Bioaffinity Technologies Warrant Stock Today

BIAFW Stock  USD 0.72  0.03  4.00%   

Performance

2 of 100

 
Weak
 
Strong
Weak

Odds Of Distress

Over 85

 
High
 
Low
Very High
BioAffinity Technologies is selling for under 0.72 as of the 30th of November 2024; that is 4 percent down since the beginning of the trading day. The stock's lowest day price was 0.72. BioAffinity Technologies has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for bioAffinity Technologies Warrant are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
1st of September 2022
Category
Healthcare
Classification
Health Care
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company was founded in 2014 and is based in San Antonio, Texas. Bioaffinity Technologies operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. More on bioAffinity Technologies Warrant

Moving together with BioAffinity Stock

  0.61ELAN Elanco Animal HealthPairCorr

Moving against BioAffinity Stock

  0.68BMY Bristol Myers Squibb Sell-off TrendPairCorr
  0.67ESPR Esperion Therapeutics Buyout TrendPairCorr
  0.61GILD Gilead SciencesPairCorr
  0.57VTRS ViatrisPairCorr
  0.57EWTX Edgewise TherapeuticsPairCorr
  0.53EBS Emergent BiosolutionsPairCorr

BioAffinity Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors)
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.320.308
Sufficiently Up
Slightly volatile
Gross Profit Margin0.30.3126
Sufficiently Down
Slightly volatile
Total Current Liabilities2.1 M2.2 M
Notably Down
Very volatile
Non Current Liabilities TotalM1.1 M
Way Up
Slightly volatile
Total AssetsM8.2 M
Way Down
Slightly volatile
Total Current AssetsMM
Slightly Up
Slightly volatile
BioAffinity Technologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioAffinity Technologies' financial leverage. It provides some insight into what part of BioAffinity Technologies' total assets is financed by creditors.
Liquidity
bioAffinity Technologies Warrant has accumulated 1.58 M in total debt. BioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity.

Net Income

(8.33 Million)
bioAffinity Technologies Warrant (BIAFW) is traded on NASDAQ Exchange in USA. It is located in 22211 West Interstate 10, San Antonio, TX, United States, 78257 and employs 75 people. BioAffinity Technologies is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry. bioAffinity Technologies Warrant has accumulated about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08.
Check BioAffinity Technologies Probability Of Bankruptcy

BioAffinity Technologies Historical Income Statement

At this time, BioAffinity Technologies' Selling General Administrative is fairly stable compared to the past year. Total Revenue is likely to climb to about 2.7 M in 2024, despite the fact that Operating Income is likely to grow to (7.6 M). View More Fundamentals

BioAffinity Stock Against Markets

BioAffinity Technologies Corporate Management

Timothy JDSecretary VPProfile
Dallas ColemanNational SalesProfile
William BautaSenior TherapeuticsProfile
Maria JDPresident, FounderProfile
Xavier MSVP OperationsProfile

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.